Jonah Feldman

A post hoc sensitivity analysis that counted use of subsequent therapies in patients censored from primary overall survival follow-up favored darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

The approval of talquetamab, a GPRC5D-targeted bispecific T-cell engager, led to discussions in 2 separate Case-Based Roundtable events on therapy sequencing selection, toxicity, and outpatient treatment.

Durable responses were seen with obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia across bone marrow blast levels, with best efficacy and tolerability in those with less than 5% blasts.

The RELIEVE study looked at real-world patients receiving trastuzumab deruxtecan based on HER2 expression status and time to next treatment including in those whose HER2 status changed during course of treatment.

At 2 separate Case-Based Roundtable events, oncologists discussed important factors that could influence their choice of frontline therapy for a patient with advanced hepatocellular carcinoma.

The role of immunotherapy continues to evolve for the treatment of patients with skin cancer, now with physicians able to choose between the use of single-agent vs dual immunotherapy treatments. In 2 separate Case-Based Roundtable events led by Alan Tan, MD, and Douglas B. Johnson, MD, MSCI, physicians considered these options for a patient with metastatic melanoma.

The OPEB-01 trial showed a potential maintenance role for olaparib, pembrolizumab, and bevacizumab in patients who responded to chemotherapy after platinum-sensitive recurrence to ovarian cancer.

The safety run-in of the LEAP-014 trial showed acceptable toxicity and antitumor responses in patients with metastatic esophageal cancer receiving pembrolizumab, lenvatinib, and chemotherapy consisting of cisplatin plus either paclitaxel or 5-fluororacil.

Results from the BRUIN study focusing on patients with chronic lymphocytic leukemia/small lymphocytic lymphoma showed benefit in patients were pretreated with Bruton tyrosine kinase inhibitors.

For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.

Investigators reported the best objective response, progression-free survival, overall survival, and safety of a B7-H3–directed antibody-drug conjugate at the 2023 World Conference on Lung Cancer.

Advances are being seen with the introduction of Menin inhibitors

Triplet therapy regimens now are on the horizon for patients with AML, thanks to ongoing research into targeted therapies.

During an interview with Targeted Oncology, Geoffrey Young, MD, PhD, discussed the impact of molecular testing, targeted therapies, and new approaches to surgical management of thyroid cancers.

Key opinion leaders discuss barriers to care for using CAR T-cell therapy for patients with large B-cell lymphoma, including time delays and lack of support for patients.

Patients treated with VT1021 for recurrent glioblastoma were found to have immune markers associated with response to treatment in a phase 1/2 study.

In an interview, Jamie L. Koprivnikar, MD, discussed the importance of a machine learning approach to genomic testing in AML.

The DeLLphi-300 trial of a bispecific T-cell engager showed favorable outcomes in patients with previously treated small cell lung cancer.

The current landscape for T-cell acute lymphoblastic leukemia has been influenced by 2 key phase 3 trials, Children’s Oncology Group AALL0434 and AALL1231.

During an interview with Targeted Oncology, Matthew A. Powell, MD, discussed the significance of the FDA approval and his presentation of the results from the RUBY trial.

A retrospective study of the CATCH-IT database provided data on patients with HIV who received immunotherapy for multiple cancer types, demonstrating safety and efficacy in most cases.

Topline results reported from the UPLIFT trial showed it did not meet its primary end point of objective response rate in the NaPi2b-positive population with ovarian cancer.

In an interview with Targeted Oncology™, Patricia Rich, MD, discussed the data presented at ASCO 2023 and other recent trials that she found most exciting and important to the field of NSCLC treatment.

Results from the CARTITUDE-2 trial of cilta-cel for multiple myeloma support the use of chimeric antigen receptor T-cell therapy earlier in therapy than what is currently approved.

During an interview with Targeted Oncology, Lindsey S. Treviño, PhD, discussed how racial and socioeconomic disparities impact access to CAR T-cell therapy, clinical trials, and more.

In an interview with Targeted Oncology, Yael C. Cohen, MD, senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, discussed the results from RedirecTT-1 she presented at ASCO 2023.

A trial of targeted treatment with improved drug delivery to the brain met its primary end point for overall survival in patients with recurrent glioblastoma.

The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.

Results from 2 trials of lisocabtagene maraleucel presented at ICML 2023 demonstrated efficacy and tolerability in patients with follicular lymphoma and mantle cell lymphoma.